XML 19 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2013
Equity [Abstract]  
Summary of Stock Option Activity

The following table summarizes stock option activity for the nine months ended September 30, 2013:

 

     Number of
Options
    Weighted
Average
Exercise Price
     Weighted
Average
Remaining
Contractual Term
(in years)
     Aggregate Intrinsic
Value (1)
 

Outstanding at December 31, 2012

     7,038,291      $ 18.90         

Granted

     345,286      $ 49.80         

Exercised

     (551,216   $ 11.72         

Forfeited

     (91,220   $ 24.98         
  

 

 

         

Outstanding at September 30, 2013

     6,741,141      $ 20.99         6.69       $ 262.5   
  

 

 

         

Vested and exercisable at September 30, 2013

     4,190,995      $ 12.60         5.58       $ 198.4   
  

 

 

         

 

(1)  The aggregate intrinsic value is calculated as the pre-tax difference between the weighted average exercise price of the underlying awards and the closing price per share of $59.94 of the Company’s common stock on September 30, 2013. The calculation excludes any awards with an exercise price higher than the closing price of the Company’s common stock on September 30, 2013. The amounts are presented in millions.
Summary of Restricted Stock Units

The following table summarizes restricted stock unit activity for the nine months ended September 30, 2013:

 

     Number of
Shares
    Weighted-
Average
Grant-Date
Fair Value
 

Unvested at December 31, 2012

     373,625      $ 39.06   

Granted

     73,993      $ 50.94   

Vested

     —          —     

Forfeited

     (12,076   $ 44.15   
  

 

 

   

Unvested at September 30, 2013

     435,542      $ 40.94   
  

 

 

   
Summary of Stock Appreciation Rights Activity

The following table summarizes stock appreciation rights activity for the nine months ended September 30, 2013:

 

     Number of
Rights
    Weighted
Average
Exercise Price
     Weighted
Average
Remaining
Contractual Term
(in years)
     Aggregate Intrinsic
Value (1)
 

Outstanding at December 31, 2012

     883,600      $ 23.91         

Granted

     —         —          

Exercised

     (34,046   $ 23.20         

Forfeited

     (18,338   $ 23.20         
  

 

 

         

Outstanding at September 30, 2013

     831,216      $ 23.95         8.19       $ 29.9   
  

 

 

         

Vested and exercisable at September 30, 2013

     345,044      $ 23.99         8.16       $ 12.4   
  

 

 

         

 

(1)  The aggregate intrinsic value is calculated as the pre-tax difference between the weighted average exercise price of the underlying awards and the closing price per share of $59.94 of the Company’s common stock on September 30, 2013. The calculation excludes any awards with an exercise price higher than the closing price of the Company’s common stock on September 30, 2013. The amounts are presented in millions.
Schedule of Black-Scholes Assumptions Used for Stock Options and Stock Appreciations Rights

The Company estimates the fair value of stock options and stock appreciation rights using the Black-Scholes valuation model, which requires the use of subjective assumptions related to the estimated stock price volatility, estimated term, estimated dividend yield and risk-free interest rate. The Black-Scholes assumptions used for stock options and stock appreciation rights granted were as follows:

 

     Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
     2013     2012     2013     2012  

Risk-free interest rate

     1.45     0.68     0.73-1.55     0.68-1.01

Estimated term (in years)

     5.25        5.28        5.24-5.50        5.28-5.48   

Estimated volatility

     68     66     68-75     66-73

Estimated dividend yield

     —         —         —         —    
Schedule of Stock-Based Compensation Expense

Stock-based compensation expense was as follows:

 

     Three Months Ended
September 30,
     Nine Months Ended
September 30,
 
     2013      2012      2013      2012  

Stock-based compensation expense recognized as:

           

R&D expense

   $ 3,765       $ 3,512       $ 11,202       $ 8,997   

SG&A expense

     5,436         4,091         14,426         8,523   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 9,201       $ 7,603       $ 25,628       $ 17,520